REVA Medical (RVALL) 10-K 17 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 15, 2014	Jun. 30, 2013
Document and Entity Information	'	'	'
Entity Registrant Name	'REVA Medical, Inc.	'	'
Entity Central Index Key	'0001496268	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$130,097,000
Entity Common Stock, Shares Outstanding	'	33,459,203	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$19,229	$38,876
Short-term investments	1,492	5,223
Prepaid expenses and other current assets	415	417
Total current assets	21,136	44,516
Property and equipment, net	3,589	2,821
Other assets	60	60
Total Assets	24,785	47,397
Current Liabilities:	'	'
Accounts payable	1,400	656
Accrued expenses and other current liabilities	2,080	1,537
Total current liabilities	3,480	2,193
Long-term liabilities	480	578
Total Liabilities	3,960	2,771
Commitments and contingencies (Note 8)	'	'
Stockholders' Equity:	'	'
Undesignated preferred stock - $0.0001 par value; 5,000,000 shares authorized; no shares issued or outstanding	'	'
Additional paid-in capital	222,331	218,210
Deficit accumulated during the development stage	-201,509	-173,587
Total Stockholders' Equity	20,825	44,626
Total Liabilities and Stockholders' Equity	24,785	47,397
Common stock	'	'
Stockholders' Equity:	'	'
Common stock	3	3
Class B common stock	'	'
Stockholders' Equity:	'	'
Common stock	'	'

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common stock, par value (in dollars per share)	$0.61	'
Undesignated preferred stock, par value (in dollars per share)	$0.00	$0.00
Undesignated preferred stock, shares authorized	5,000,000	5,000,000
Undesignated preferred stock, shares issued	0	0
Undesignated preferred stock, shares outstanding	0	0
Common stock	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	33,270,053	33,132,203
Common stock, shares outstanding	33,270,053	32,132,203
Class B common stock	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	0	0
Common stock, shares outstanding	0	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended			187 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Operating Expense:	'	'	'	'
Research and development	$19,212	$15,822	$13,401	$122,756
General and administrative	8,731	8,043	7,695	44,661
Loss from operations	-27,943	-23,865	-21,096	-167,417
Other Income (Expense):	'	'	'	'
Interest income	30	92	188	1,405
Related party interest expense	'	'	'	-21,113
Interest expense	'	'	'	-952
Interest from amortization of notes payable premium	'	'	'	2,283
Gain on change in fair value of preferred stock rights and warrant liabilities	'	'	'	1,795
Loss on extinguishment of notes payable	'	'	'	-13,285
Other expense	-9	-3	'	-52
Net Loss	-27,922	-23,776	-20,908	-197,336
Cumulative dividends and deemed dividends on Series H convertible preferred stock	'	'	'	-10,695
Net Loss Attributable to Common Stockholders	-27,922	-23,776	-20,908	-208,031
Net Loss Per Common Share:	'	'	'	'
Net loss per share, basic and diluted (in dollars per share)	($0.84)	($0.72)	($0.64)	'
Shares used to compute net loss per share, basic and diluted (in shares)	33,124,655	33,072,058	32,777,509	'
Comprehensive Loss:	'	'	'	'
Net Loss	-27,922	-23,776	-20,908	-197,336
Cumulative dividends and deemed dividends on Series H convertible preferred stock	'	'	'	-10,695
Comprehensive Loss Attributable to Common Stockholders	($27,922)	($23,776)	($20,908)	($208,031)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended			187 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Cash Flows from Operating Activities:	'	'	'	'
Net loss	($27,922)	($23,776)	($20,908)	($197,336)
Non-cash adjustments to reconcile net loss to net cash used for operating activities:	'	'	'	'
Depreciation and amortization	892	677	452	4,862
Loss (gain) on property and equipment disposal and impairment	1	1	-1	586
Stock-based compensation	4,090	3,497	3,089	12,705
Interest on notes payable	'	'	'	8,562
Repayment premium on notes payable	'	'	'	11,100
Loss on change in fair value of preferred stock warrant liability	'	'	'	970
Gain on change in fair value of preferred stock rights liability	'	'	'	-2,765
Loss on extinguishment of notes payable	'	'	'	13,285
Other non-cash expenses	18	80	28	168
Changes in operating assets and liabilities:	'	'	'	'
Prepaid expenses and other current assets	2	496	-148	-415
Other assets	'	'	-60	-60
Accounts payable	549	-218	-224	1,205
Accrued expenses and other current liabilities	525	522	375	1,982
Long-term liabilities	-98	60	459	421
Net cash used for operating activities	-21,943	-18,661	-16,938	-144,730
Cash Flows from Investing Activities:	'	'	'	'
Purchases of property and equipment	-1,466	-1,949	-883	-9,009
Sales of property and equipment	'	'	6	167
Purchases of investments	-1,492	-1,989	-5,226	-26,593
Maturities of investments	5,223	1,992	'	25,101
Net cash provided by (used for) investing activities	2,265	-1,946	-6,103	-10,334
Cash Flows from Financing Activities:	'	'	'	'
Proceeds from issuances of convertible preferred stock, net	'	'	'	68,917
Proceeds from issuances of common stock	31	322	33	85,319
Initial public offering costs, net	'	'	422	-8,068
Proceeds from exercises of warrants	'	'	'	263
Repurchases of stock	'	'	'	-638
Proceeds from issuances of notes payable	'	'	'	28,600
Repayments of notes payable	'	'	'	-100
Net cash provided by financing activities	31	322	455	174,293
Net increase (decrease) in cash and cash equivalents	-19,647	-20,285	-22,586	19,229
Cash and cash equivalents at beginning of period	38,876	59,161	81,747	'
Cash and Cash Equivalents at End of Period	19,229	38,876	59,161	19,229
Supplemental Cash and Non-Cash Information: (also see Consolidated Statements of Stockholders' Equity for non-cash transactions that arose upon our IPO in December 2010)	'	'	'	'
Cash paid for interest	'	'	'	126
Preferred stock issued upon conversion of notes payable	'	'	'	7,950
Property and equipment in accounts payable	$195	$99	$571	$195

Consolidated_Statements_of_Con

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)

Total

June 1998 to July 1999

June 3, 1998 (inception) to November 30, 1999

December 1999 to October 2000

February 2001 to February 2010

May-01

Aug-04

Jul-05

Jul-02

Dec-10

December 1, 1999 (recapitalization) to December 31, 2010

Voting Common Stock

Voting Common Stock

Voting Common Stock

Voting Common Stock

Voting Common Stock

Voting Common Stock

Voting Common Stock

Non - Voting Common Stock

Non - Voting Common Stock

Non - Voting Common Stock

Series A Preferred Stock

Series E Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series F Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Convertible Preferred Stock

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Additional Paid-in Capital

Deficit Accumulated During the Development Stage

Deficit Accumulated During the Development Stage

Deficit Accumulated During the Development Stage

Deficit Accumulated During the Development Stage

Deficit Accumulated During the Development Stage

In Thousands, except Share data, unless otherwise specified

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

June 1998 to July 1999

Dec-99

December 1999 to October 2000

February 2001 to February 2010

Aug-00

Dec-10

May-01

Aug-04

Dec-10

Dec-99

2003

USD ($)

2007 to 2010

2004

Dec-10

Series A Preferred Stock

Series A and B Preferred Stock

Series C Preferred Stock

Series D Preferred Stock

Series E Preferred Stock

Series G-1 Preferred Stock

Series G-1 Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

USD ($)

June 1998 to July 1999

Dec-99

December 1999 to October 2000

February 2001 to February 2010

May-01

Aug-04

Jul-05

Jul-02

Dec-10

Series A Preferred Stock

Series E Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series F Preferred Stock

USD ($)

June 3, 1998 (inception) to November 30, 1999

Dec-99

December 1, 1999 (recapitalization) to December 31, 2010

Series H Convertible Preferred Stock

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Dec-99

Dec-99

Jul-00

Feb-01

June 2001 to February 2002

USD ($)

Oct-04

USD ($)

2007 to 2010

2007

Jun-10

Mar-10

May-10

2007 to 2010

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Dec-99

2003

USD ($)

2007 to 2010

2004

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Balance at Jun. 02, 1998

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, value, new issues

'

$278

'

$106

'

'

'

'

'

$84,278

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

'

'

$1,197

$1,100

$2,000

$15,000

'

$7,000

'

$42,000

$5,164

'

'

'

'

'

$278

'

$106

'

'

'

'

'

$84,277

'

'

'

'

'

'

'

'

'

'

Stock issued during period, value, new issues (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

2,452,088

'

910,500

'

'

7,727,273

'

'

'

'

'

'

'

'

'

'

1,029,833

558,374

819,673

2,450,980

'

709,939

'

6,454,986

793,629

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Loss

'

'

-492

'

'

'

'

'

'

'

-124,238

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-492

'

-124,238

'

Recapitalization of Company December 1999

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-492

'

'

'

'

'

'

'

'

'

'

'

'

'

'

492

'

'

Stock issued in exchange for common stock on a 1-for-1 basis upon recapitalization of Company

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-185

'

'

'

'

'

185

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-185

'

'

'

'

'

'

'

'

'

Stock issued in exchange for common stock on a 1-for-1 basis upon recapitalization of Company (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,618,058

'

'

'

'

'

'

'

'

'

'

'

'

'

1,618,058

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance costs on preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-500

'

-100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock issued upon conversion of notes payable and accrued interest

'

'

'

'

'

'

'

'

'

28,665

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,664

'

'

'

'

'

'

'

'

'

'

Preferred stock issued upon conversion of notes payable and accrued interest (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,638,778

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

304,260

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of rights in 2007 of possible future issuances of Series H preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,905

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Realized value of rights to possible future issuances of Series H preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,140

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deemed dividends on Series H preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,363

'

'

'

'

'

'

-4,363

Cumulative dividends on Series H preferred stock at $0.3995 per share per year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,332

'

'

'

'

'

'

'

'

'

'

6,332

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-6,030

'

'

'

'

'

'

-302

Stock repurchased during period

'

'

'

'

'

'

-88

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-550

'

'

'

'

'

'

'

'

-88

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchased during period (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-189,500

'

'

-353,329

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-461,071

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds in June from Series H preferred stock escrow fund

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

484

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reissuance of Series H preferred stock and warrants to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

550

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reissuance of Series H preferred stock and warrants to purchase common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

461,071

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of beneficial conversion feature on convertible notes payable

365

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

365

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants to purchase Series E and Series F preferred stock reclassified to long-term liability upon adoption of accounting pronouncement

-435

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-435

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants to purchase of common stock issued in connection stock issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,545

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,545

'

'

'

'

'

'

'

'

'

'

'

'

'

1,545

'

'

'

'

'

'

Change in fair value of embedded conversion features of notes payable

12,243

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,243

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants issued in connection with notes payable to purchase shares of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

315

'

'

230

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

315

'

'

'

'

'

'

'

'

Common stock issued upon exercise of stock options for cash

'

'

'

'

456

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

456

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued upon exercise of stock options for cash (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,058,429

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-voting common stock issued for technology license valued, value

'

'

'

'

'

13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-voting common stock issued for technology license valued, value (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

481,813

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-voting common stock vested

'

'

'

'

'

'

'

60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60

'

'

'

'

'

'

'

'

'

'

'

'

Non-cash distribution of assets to stockholders

'

'

'

'

'

'

'

'

-60

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-60

'

'

'

'

'

'

'

'

'

'

'

Common stock issued December upon conversion of preferred convertible stock

'

'

'

'

'

'

'

'

'

78,552

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

-78,552

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

78,551

'

'

'

'

'

'

'

'

'

'

Common stock issued December upon conversion of preferred convertible stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

14,929,713

'

'

'

'

'

'

'

'

-14,739,732

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued December upon conversion of non-voting common stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

128,484

'

'

-128,484

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Transfer of repayment premium on long-term notes payable in December upon conversion of notes

'

'

'

'

'

'

'

'

'

11,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,100

'

'

'

'

'

'

'

'

'

'

Issuance costs of initial public offering

-8,490

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-8,490

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

2,028

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,028

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued December for cumulative dividends on Series H convertible preferred stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

973,227

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Transfer of preferred stock warrant liability in December upon exercise of warrants

'

'

'

'

'

'

'

'

'

1,770

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,770

'

'

'

'

'

'

'

'

'

'

Common stock issued December upon exercise of warrants for cash at $3.28 to $6.5066 per share

'

'

'

'

'

'

'

'

'

263

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

263

'

'

'

'

'

'

'

'

'

'

Common stock issued upon exercise of warrants (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

49,535

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued December upon net exercise of warrants at $3.28 to $6.5066 per share (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

700,034

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2010

81,947

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

210,847

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-128,903

'

'

'

'

Balance (in shares) at Dec. 31, 2010

'

'

'

'

'

'

'

'

'

'

'

32,760,503

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Loss

-20,908

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-20,908

'

'

'

'

Common stock issued upon exercise of stock options for cash

33

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued upon exercise of stock options for cash (in shares)

'

'

'

'

'

'

'

'

'

'

'

45,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

3,089

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,089

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted common stock issued under equity incentive plan (in shares)

'

'

'

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Refund of taxes withheld from initial public offering proceeds in December 2010

422

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

422

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2011

64,583

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

214,391

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-149,811

'

'

'

'

Balance (in shares) at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

32,810,503

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Loss

-23,776

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-23,776

'

'

'

'

Common stock issued upon exercise of stock options for cash

322

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

322

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued upon exercise of stock options for cash (in shares)

'

'

'

'

'

'

'

'

'

'

'

288,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

3,497

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,497

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted common stock issued under equity incentive plan (in shares)

'

'

'

'

'

'

'

'

'

'

'

33,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2012

44,626

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

218,210

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-173,587

'

'

'

'

Balance (in shares) at Dec. 31, 2012

'

'

'

'

'

'

'

'

'

'

'

33,132,203

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Loss

-27,922

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-27,922

'

'

'

'

Common stock issued upon exercise of stock options for cash

31

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued upon exercise of stock options for cash (in shares)

'

'

'

'

'

'

'

'

'

'

'

50,350

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

4,090

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,090

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted common stock issued under equity incentive plan (in shares)

'

'

'

'

'

'

'

'

'

'

'

87,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2013

$20,825

'

'

'

'

'

'

'

'

'

'

$3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$222,331

'

'

'

'

'

'

'

'

'

'

'

'

'

'

($201,509)

'

'

'

'

Balance (in shares) at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

33,270,053

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consolidated_Statements_of_Con1

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (USD $)

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2011

Feb. 28, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2011

Feb. 28, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Aug-00

Dec-10

Minimum

Minimum

Minimum

Minimum

Minimum

Minimum

Minimum

Maximum

Maximum

Maximum

Maximum

Maximum

Maximum

Maximum

Series A Preferred Stock

Series B Preferred Stock

Series C Preferred Stock

Series D Preferred Stock

Series E Preferred Stock

Series E Preferred Stock

Series G-1 Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series H Convertible Preferred Stock

Series F Preferred Stock

Nonvoting Common Stock

Nonvoting Common Stock

June 1998 to July 1999

December 1999 to October 2000

February 2001 to February 2010

Dec-10

June 1998 to July 1999

December 1999 to October 2000

February 2001 to February 2010

Dec-10

Dec-99

Dec-99

Jul-00

Feb-01

June 2001 to February 2002

2003

Oct-04

2007 to 2010

2007

Mar-10

May-10

2007 to 2010

2004

May-01

Aug-04

Common stock, par value (in dollars per share)

$0.00

$10.91

$0.61

$0.25

'

$0.00

$0.10

$0.10

'

$1.40

$1.40

'

$0.67

$0.20

$1.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.25

$0.25

Preferred stock issued for cash, per share

'

'

'

'

$0.10

'

'

'

'

'

'

$1.40

'

'

'

'

$1.01

$1.20

$1.97

$2.44

$6.12

'

$9.86

'

$6.51

$6.51

'

'

'

'

'

'

Preferred stock, shares repurchases through warrants (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

82,805

'

'

'

'

'

'

'

53,354

'

'

Preferred stock, cumulative dividends

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.40

'

'

'

'

'

'

'

'

Common stock, shares repurchases through warrants (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

92,214

92,214

1,449,725

'

'

'

Common stock, purchased value per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.99

$0.99

'

'

'

'

Exercise of warrant, par value

'

'

'

'

'

'

'

'

$3.28

'

'

'

'

'

'

$6.51

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description_of_Business

Description of Business	12 Months Ended
	Dec. 31, 2013
Description of Business	'
Description of Business	'
	1.  Description of Business
	REVA Medical, Inc. (“REVA” or the “Company”) was incorporated in California in 1998 under the name MD3, Inc. In March 2002 we changed our name to REVA Medical, Inc. In October 2010 we reincorporated in Delaware. We established a non-operating wholly owned subsidiary, REVA Germany GmbH, in 2007. In these notes the terms “us,” “we,” or “our” refer to REVA and our consolidated subsidiary unless context dictates otherwise.
	We are currently developing and testing a bioresorbable stent to treat vascular disease in humans. We do not yet have a product available for sale; our product(s) will become available following completion of required clinical studies with acceptable data and when, and if, we receive regulatory approval. During 2013 we enrolled 111 patients in a clinical trial of our current stent product; if the data from this trial is acceptable, we intend to apply for a European CE Marking, the regulatory approval that would allow us to commercialize the product.
	In December 2010 we completed an initial public offering (the “IPO”) of our common stock in Australia. We issued 7,727,273 shares of common stock for net proceeds of $75.79 million; we registered this stock with the U.S. Securities and Exchange Commission (“SEC”) and, consequently, became an SEC filer. Our stock is traded in the form of CHESS Depository Interests (“CDIs”) on the Australian Securities Exchange (“ASX”); each share of our common stock is equivalent to ten CDIs. Our trading symbol is “RVA.AX.”

Stage_of_Company_Capital_Resou

Stage of Company, Capital Resources, and Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Stage of Company, Capital Resources, and Basis of Presentation	'
Stage of Company, Capital Resources, and Basis of Presentation	'
	2.  Stage of Company, Capital Resources, and Basis of Presentation
	Development Stage:  We are considered a “development stage” entity, as we have not yet generated revenues from the sale of products. We have been researching and developing new technologies and product applications and have conducted human clinical trials of our bioresorbable stent. We will continue as a development stage entity, including reporting “inception to-date” amounts and cumulative equity transactions, until such time, if any, as we generate revenue.
	Capital Resources and Going Concern:  We have experienced recurring losses and negative cash flows from operating activities since our inception and, as of December 31, 2013, we had a deficit accumulated during the development stage of $201,509,000. Until we generate a level of revenue to support our cost structure, we expect to continue to incur substantial operating losses and net cash outflows. While we had cash and investments totaling $20,721,000 as of December 31, 2013, we do not believe these resources will be sufficient to meet our operating and capital needs through 2014.
	We intend to fund our ongoing activities by utilizing our current cash and investments and by raising additional capital through equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. If we are unable to raise sufficient additional capital, we may be compelled to reduce the scope of our operations and planned capital expenditures or sell certain assets, including intellectual property assets.
	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Given our current cash and investment balances and our planned operating activities, our recurring losses and negative cash flows from operating activities raise substantial doubt about our ability to continue as a going concern. Even if we are able to raise additional capital, we may never become profitable, or if we do attain profitable operations, we may not be able to sustain profitability and positive cash flows on a recurring basis.
	Basis of Presentation:  We have prepared the accompanying consolidated financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of REVA and our wholly owned subsidiary, REVA Germany GmbH. All intercompany transactions and balances, if any, have been eliminated in consolidation.
	Use of Estimates:  In order to prepare our financial statements in conformity with accounting principles generally accepted in the United States, we are required to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Our most significant estimates relate to, or have related to, expense accruals and fair market value determinations of notes payable and embedded conversion features, common and preferred stock warrants, preferred stock rights liability, and stock-based compensation. Actual results could differ from our estimates.
	Reclassifications:  Certain prior year amounts within the consolidated statements of cash flows and within Note 5 Income Taxes have been reclassified to conform to the current year presentation. These reclassifications had no impact on the net decreases in cash and cash equivalents or the provision for income taxes as previously reported.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies	'
Significant Accounting Policies	'
	3.  Significant Accounting Policies
	Cash and Cash Equivalents:  All highly liquid investments with original maturities of three months or less are classified as cash equivalents.
	Investments:  Excess cash is invested in high-quality marketable securities. Our investments are classified as either short- or long-term based on their maturity dates. Investments with a maturity of less than one year are classified as short-term; all others are classified as long-term. We have categorized the investments as “held-to-maturity” based on our intent and ability to hold to maturity. Our investments are stated at cost; their fair value is determined each reporting period through quoted market prices of similar instruments in active markets. During the reporting period there were no declines in fair value that were deemed to be other than temporary.
	Property and Equipment:  Property and equipment is stated at cost, less accumulated depreciation and amortization. Depreciation is determined using the straight-line method over the estimated useful lives of the related assets, generally three to five years. Amortization of leasehold improvements is determined using the straight-line method over the lesser of the useful life of the asset or the term of the underlying lease. Upon disposition or retirement of an asset, its cost and related accumulated depreciation or amortization are removed from the accounts and any gain or loss is recognized in the consolidated statement of operations.
	Patents:  Costs related to patent development, filing, and maintenance are expensed as incurred since the underlying technology associated with these assets is purchased or incurred in connection with our research and development efforts and the future realizable value cannot be determined.
	Impairment of Long-Lived Assets:  We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and exceeds its undiscounted future cash flows. The amount of impairment, if any, is determined by comparing an asset’s estimated fair value to the asset’s respective carrying amount. During the years ended December 31, 2011, 2012, and 2013 we determined there were no indications of asset impairment. During the period from June 3, 1998 (inception) through December 31, 2013, we recorded $502,000 in losses from impairment of long-lived assets.
	Concentrations of Credit Risk:  Our financial instruments, which potentially subject us to concentration of credit risk, comprise cash, cash equivalents, and investments. We maintain our cash and cash equivalents in bank accounts, the balances of which generally exceed limits that are insured by the Federal Deposit Insurance Corporation. Our investments are held in custody by a large financial asset manager in the United States. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which the assets are held. Additionally, we maintain our cash and investments in accordance with our investment policy, which is designed to maintain safety and liquidity. We have not realized any losses in our investments and believe we are not exposed to significant credit risk related to our cash and cash equivalents.
	Research and Development:  Research and development costs are expensed as incurred. These costs include salaries, employee benefits, laboratory supplies, consulting services, manufacturing products and services, preclinical and clinical costs, technology license fees, laboratory equipment depreciation, facility costs, and certain indirect costs.
	Segment Information:  We operate in one business segment, which is the development and commercialization of medical devices.
	Income Taxes:  We account for income taxes using the asset and liability method, under which the current income tax expense or benefit is the amount of income tax expected to be payable or refundable in the current year. Deferred tax assets and liabilities are recorded for the estimated future tax consequences of temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases, and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled.
	We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of our deferred tax assets will not be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.
	We account for the uncertainty in income tax components based on tax positions taken or expected to be taken in a tax return. To recognize a benefit, a tax position must be more likely than not to be sustained upon examination by taxing authorities. We do not recognize tax benefits that have a less than 50 percent likelihood of being sustained. Our policy is to recognize interest and tax penalties related to unrecognized tax benefits in income tax expense; no interest or tax penalties on uncertain tax benefits have been recorded through December 31, 2013.
	We are subject to taxation in U.S. and California jurisdictions. As of December 31, 2013, our tax years beginning December 1, 1999 remain subject to examination by taxing authorities.
	Stock-Based Compensation:  We account for stock-based compensation by measuring and recognizing expense for all stock-based payments made to employees and directors based on estimated grant date fair values. We use the straight-line method to allocate compensation expense to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimate the fair value of stock-based awards to employees and directors using the Black-Scholes option valuation model. The Black-Scholes model requires the input of assumptions, including volatility, the expected term, and the fair value of the underlying common stock on the date of grant, among other inputs. We record the option value to compensation expense based on the financial statement category for which an optionee’s services are rendered and cash compensation is recorded. We adjust stock-based compensation expense for estimated option forfeitures based on our five-year historical average of actual forfeitures.
	We account for stock options issued to consultants as expense at their fair value over the related service period, as determined in accordance with authoritative guidance. We revalue the consultants’ stock options as they vest.
	Foreign Currency:  The functional currency of our subsidiary REVA Germany GmbH is the Euro. Balance sheet accounts of our subsidiary are translated into United States dollars using the exchange rate in effect at the balance sheet date while expenses are translated using the average exchange rate in effect during the period. Gains and losses arising from translation of our subsidiary’s financial statements are recorded to other comprehensive income (loss). These gains and losses, in the aggregate, were insignificant through December 31, 2013.
	Net Loss Per Common Share:  Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method, as applicable. For purpose of this calculation, unvested restricted stock and stock options are considered to be common stock equivalents and are included in the calculation of diluted net loss per share only when their effect is dilutive.
	During the year ended December 31, 2011, we excluded options to purchase common stock of 3,324,046 shares and during the years ended December 31, 2012 and 2013, we excluded options to purchase common stock of 3,300,039 and 3,901,316 shares, respectively, and excluded 17,648 and 96,347 shares, respectively, of restricted common stock from the computation of diluted net loss per share because including them would have been antidilutive.
	Fair Value Measurements:  We measure the fair value of our financial and non-financial assets and liabilities at each reporting date. Fair value is defined as the exchange price at which an asset or liability would be transferred in the principal or most advantageous market in an orderly transaction between market participants as of a measurement date. Accounting guidance provides an established hierarchy to be used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs; observable inputs are required to be used when available. Observable inputs are those used by market participants to value an asset or liability and are developed based on market data obtained from sources independent of us. Unobservable inputs are those that reflect our assumptions about factors that market participants would use to value an asset or liability. Fair value measurements are classified and disclosed in one of the following three categories:
	Level 1 – Quoted market prices for identical assets or liabilities in active markets at the measurement date;
	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of an asset or liability; and,
	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of an asset or liability, including management’s best estimate of the factors that market participants would use in pricing an asset or liability at the measurement date.
	We apply fair value accounting to our cash equivalents and investments. The fair values of our investments, determined from “Level 2” inputs were as follows:
		Cost		Gross			Fair
				Unrealized			Value
				Losses
		(in thousands)
	As of December 31, 2012:
	Time deposits due in one year or less	$	5,223	$	(8	)	$	5,215
	As of December 31, 2013:
	Time deposits due in one year or less	$	1,492	$	(4	)	$	1,488
	Financial Statement Components Discontinued upon IPO:  Concurrent with the completion of our Initial Public Offering in December 2010, all of our outstanding convertible preferred stock, non-voting common stock, notes payable, and accrued interest on notes payable converted to common stock. Additionally, all outstanding warrants were exercised for common stock, either through a cash payment to us or on a net exercise basis. We also issued common stock for cumulative dividends on our Series H convertible preferred stock. Those debt and equity instruments, including accounting for warrant liabilities, note and warrant valuations, and deemed and cumulative dividends, had no effect on our financial statements after December 2010.
	Recent Accounting Pronouncements:  In July 2013, the Financial Accounting Standards Board issued Accounting Standards Update No. 2013-11 (“ASU 2013-11”), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years beginning after December 15, 2013. We intend to adopt this guidance at the beginning of 2014; we do not believe the adoption of this standard will have a material impact on our financial position, results of operations or related financial statement disclosures.

Balance_Sheet_Details

Balance Sheet Details	12 Months Ended
	Dec. 31, 2013
Balance Sheet Details	'
Balance Sheet Details	'
	4.  Balance Sheet Details
		December 31,
		2012			2013
		(in thousands)
	Property and equipment:
	Furniture, office equipment, and software	$	569		$	656
	Laboratory equipment	3,816			4,896
	Leasehold improvements	1,838			2,305
		6,223			7,857
	Accumulated depreciation and amortization	(3,402		)	(4,268		)
		$	2,821		$	3,589
	Accrued expenses and other current liabilities:
	Accrued salaries and other employee costs	$	1,123		$	1,371
	Accrued operating expenses	288			560
	Accrued use taxes and other	126			149
		$	1,537		$	2,080

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Income Taxes	'
	5.  Income Taxes
	We have reported net losses for all periods through December 31, 2013; therefore, no provision for income taxes has been recorded. The following table provides the reconciliation between income taxes computed at the federal statutory rate and our provision for income taxes:
		Year Ended December 31,
		2011			2012			2013
		(in thousands)
	Federal income taxes at 34%	$	(7,109	)	$	(8,084	)	$	(9,493	)
	State income taxes, net of federal benefit	(1,219		)	(1,363		)	(1,553		)
	Research and development credits	(828		)	(240		)	(1,425		)
	Stock-based compensation expense	133			131			191
	Increase in valuation allowance	8,079			59,186			11,622
	Reinstatement of deferred tax assets for net operating loss and tax credit carryover deferred tax assets	—			(50,311		)	—
	Expiration of state net operating losses	—			673			677
	Other	944			8			(19		)
	Provision for income taxes	$	—		$	—		$	—
	Our deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows:
		December 31,
		2012			2013
		(in thousands)
	Deferred Tax Assets:
	Net operating loss carryforwards	$	52,895		$	61,629
	Research and development credits	4,853			6,277
	Stock-based compensation expense	2,749			4,182
	Depreciation	177			230
	Accrued operating expenses	—			12
	Other	327			293
		61,001			72,623
	Valuation Allowance	(61,001		)	(72,623		)
	Net Deferred Income Taxes	$	—		$	—
	At December 31, 2013 we had aggregate federal and California state net operating loss carryforwards of approximately $158,916,000 and $132,037,000, respectively, which may be available to offset future taxable income for income tax purposes. The federal net operating loss carryforwards begin to expire in 2019 and the California carryforwards begin to expire in 2014, with $7,712,000 expiring in 2014.
	At December 31, 2013, we also had federal and California state research tax credit carryforwards of approximately $5,278,000 and $4,684,000, respectively. The federal carryforwards begin to expire in 2020 and the California carryforwards have no expiration.
	A total of $267,000 of the federal and California net operating loss relates to excess tax benefits generated from stock compensation that will be recorded as an increase to additional paid-in capital if, and when, realized.
	Under Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of our net operating loss and research tax credit carryforwards to offset taxable income may be limited based on cumulative changes in ownership. An analysis of the impact of this provision from December 1, 1999 through December 31, 2013 has been performed and it was determined that, although ownership changes had occurred, the carryovers should be available for utilization by the Company before they expire, provided we generate sufficient future taxable income. Based on the results of this analysis, in the prior year, we reinstated the deferred tax assets arising from the net operating loss and tax credit carryforwards, with a corresponding increase to the valuation allowance for the year ended December 31, 2012. Future ownership changes could result in further limitations and may impact the realizability of these loss and credit carryforwards in future periods.
	At December 31, 2013, we had deferred tax assets of $72,623,000 primarily comprising net operating loss and research tax credit carryforwards. We have established a valuation allowance against our deferred tax assets due to the uncertainty surrounding the Company’s ability to generate future taxable income to realize those assets. The change in the valuation allowance for the years ending December 31, 2012 and 2013 was $59,187,000 and $11,622,000, respectively.
	We recognize a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more-likely-than-not recognition at the effective date to be recognized. At December 31, 2013, the unrecognized tax benefits recorded were approximately $2,490,000. We do not anticipate a significant change in the unrecognized tax benefits within the next 12 months.
	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits for 2012 and 2013, excluding interest and penalties, is as follows:
		December 31,
		2012			2013
		(in thousands)
	Balance at Beginning of Year	$	—		$	1,954
	Additions for tax positions (prior years)	1,833			167
	Additions for tax positions (current year)	121			369
	Balance at End of Year	$	1,954		$	2,490
	Due to our valuation allowance position, none of the unrecognized tax benefits, if recognized, will impact the Company’s effective tax rate.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2013
Stock-Based Compensation	'
Stock-Based Compensation	'
	6.  Stock-Based Compensation
	Our 2010 Equity Incentive Award Plan was a follow-on to our 2001 Stock Option/Stock Issuance Plan and the two plans are collectively referred to as the “Plan.” The Plan provides for restricted stock awards as well as for grants of incentive and non-qualified stock options to purchase our common stock at a price per share equal to the closing market price of our stock on the date of option grant. The number of shares reserved under the Plan may be increased annually by up to three percent of the outstanding stock of the Company.
	On January 1, 2013, an additional 993,966 shares were added, resulting in a total of 6,545,884 shares reserved under the Plan as of December 31, 2013.
	The term of the options granted under the Plan may not exceed ten years. Vesting periods of stock awards and option grants are determined by the Company’s board of directors and are generally four- or five-year periods. All options are immediately exercisable upon grant and are subject to repurchase by us at the exercise price in the event an optionee terminates service prior to being fully vested.
	Option activity under the Plan is as follows:
							Weighted
				Weighted			Average
				Average			Remaining		Aggregate
		Options		Exercise			Contractual		Intrinsic
		Outstanding		Price			Term (years)		Value
	Balance at December 31, 2010	3,016,800		$	5.96
	Granted	401,000		$	13.7
	Cancelled	(73,800	)	$	4.62
	Exercised	(40,000	)	$	0.79
	Balance at December 31, 2011	3,304,000		$	6.99
	Granted	544,000		$	5.95
	Cancelled	(9,300	)	$	12.64
	Exercised	(288,700	)	$	1.11
	Balance at December 31, 2012	3,550,000		$	7.3
	Granted	589,500		$	5.36
	Cancelled	(42,500	)	$	2
	Exercised	(50,350	)	$	0.61
	Balance at December 31, 2013	4,046,650		$	7.15		7.17		$	3,290,000
	Vested at December 31, 2013	2,738,501		$	7.07		5.38		$	3,267,000
	Vested and Expected to Vest at December 31, 2013	4,014,994		$	7.03		6.34		$	3,289,000
	The unvested portion of outstanding options as of December 31, 2013 has vesting dates scheduled through 2017. Following is the vesting activity under the Plan for the year ended December 31, 2013:
				Weighted
				Average
		Options		Grant Date
		Outstanding		Fair Value
	Unvested Options at December 31, 2012	1,471,925		$	5.16
	Granted	589,500		$	2.95
	Vested	(747,443	)	$	5.13
	Forfeited	(5,833	)	$	3.77
	Unvested Options at December 31, 2013	1,308,149		$	4.2
	We awarded 33,000 and 87,500 shares of restricted stock during the years ended December 31, 2012 and 2013, respectively, all of which vest at the rate of 25 percent annually on each award anniversary date.
	No tax benefits arising from stock-based compensation have been recognized in the consolidated statements of operations through December 31, 2013.
	Stock Options and Restricted Stock to Employees:  We account for option grants and restricted stock awards to employees based on the estimated fair values on the date of grant or award, with the resulting stock-based compensation recorded over the vesting period on a straight-line basis. We include non-employee directors as employees for this purpose.
	Expense recorded for employee options and awards under the Plan is as follows:
		Year Ended December 31,
		2011			2012			2013
		(in thousands)
	Research and development	$	688		$	832		$	1,069
	General and administrative	2,452			2,647			2,965
	Total stock-based compensation	$	3,140		$	3,479		$	4,034
	At December 31, 2013, we had approximately $4,587,000 of total unrecognized compensation costs related to unvested employee options that are expected to be recognized over a weighted average period of 1.51 years.
	The fair value of options granted was estimated using the following weighted-average assumptions:
		Year Ended December 31,
		2011		2012		2013
	Risk-free interest rate	2.68	%	1.03	%	1.38	%
	Expected volatility of common stock	63.9	%	62.1	%	60.1	%
	Expected life in years	6.25		6.25		6.25
	Dividend yield	0	%	0	%	0	%
	The assumed risk-free interest rate was based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term equal to the expected life of the option. The assumed volatility was calculated from the historical market prices of a selected group of publicly traded companies considered to be our peers. We used peer group data due to the fact that we have limited historical trading data. The expected option life was calculated using the simplified method under the accounting standard for stock compensation and a ten-year option expiration. The simplified method is used since we believe our future option activity as a public company will differ from that of our own historical experience. The expected dividend yield of zero reflects that we have not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.
	A summary of the grant date fair value and intrinsic value information of options granted to employees is as follows:
		Year Ended December 31,
		2011			2012			2013
		(in thousands, except per share data)
	Weighted average grant date fair value per share	$	8.35		$	3.43		$	2.95
	Intrinsic value of options exercised	$	249		$	1,392		$	231
	Total fair value of options vested during period	$	3,140		$	3,802		$	3,809
	Stock Options to Consultants:  We account for stock options granted to consultants at their fair value. Under this method, the fair value is estimated at each reporting date during the vesting period using the Black-Scholes option-pricing model. The resulting stock-based compensation is recorded over the consultant’s service period. No options were issued to consultants during 2011 or 2012;  options to purchase 100,000 shares of common stock were granted to consultants in October 2013. The fair value of these awards was determined with the following assumptions:  Assumed risk-free interest rate of 1.2 to 3.0 percent; assumed volatility of 59 to 62 percent; expected option life of 5.7 to 9.8 years; and, expected dividend yield of zero percent. The total fair value of consultant options vested during 2011, 2012 and 2013 was $57,000, $42,000 and $40,000, respectively. The weighted average fair value of unvested consultant options at December 31, 2011, 2012, and 2013 was estimated to be $5.24, $4.37, and $2.84 per share, respectively, based on the following assumptions:
		Year Ended December 31,
	2011		2012		2013
Risk-free interest rate	1.62	%	1.18	%	2.96	%
Expected volatility of common stock	62.1	%	62.1	%	59.4	%
Expected life – years	7.71		6.71		9.45
Dividend yield	0	%	0	%	0	%
Consultant stock-based compensation expense, or income if the fair value declined in a reporting period, is recorded to the financial statement line item for which the optionee’s services are rendered. Expense or (income) recorded for consultant stock options under the Plan is as follows:
	Year Ended December 31,
	2011			2012			2013
	(in thousands)
Research and development	$	(51	)	$	18		$	9
General and administrative	—			—			47
Total stock-based compensation	$	(51	)	$	18		$	56
Non-Plan Options:  Prior to establishment of the Plan, we had issued non-qualified options to purchase common stock under terms similar to those of the Plan. As of December 31, 2010, a total of 10,000 of these options were outstanding. During the year ended December 31, 2011, a total of 5,000 of the options were exercised and 5,000 expired; none remained outstanding as of December 31, 2011. All stock-based compensation expense related to these options was recorded prior to 2010.

Retirement_Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2013
Retirement Plan	'
Retirement Plan	'
	7.  Retirement Plan
	In 2003 we adopted a qualified 401(k) profit sharing plan (the “401(k) Plan”) for the benefit of our employees. Employees are eligible to participate in the 401(k) Plan the month following hire and may defer up to the maximum allowed under IRS regulations, on an annual basis. We are required to match 25 percent of an employee’s deferral amount, up to a maximum of four percent of the employee’s compensation. We may, at our discretion, make additional contributions. Employees are immediately vested in the employer matching contributions. Our contributions to the 401(k) Plan were $40,000, $46,000, $52,000, and $309,000 for the years ended December 31, 2011, 2012, and 2013 and for the period from June 3, 1998 through December 31, 2013, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies.	'
Commitments and Contingencies	'
	8.  Commitments and Contingencies
	We have licensed certain patents and other intellectual property rights related to the composition and coating of our bioresorbable stent and our other biomaterial products. Terms of these licenses include provisions for royalty payments on any future sales of products, if any, utilizing this technology, with provisions for minimum royalties once product sales begin. The amount of royalties varies depending upon type of product, use of product, stage of product, location of sale, and ultimate sales volume, and ranges from a minimum of approximately $25 per unit to a maximum of approximately $100 per unit sold, with license provisions for escalating minimum royalties that could be as high as $2.2 million per year. Additionally, in the event we sublicense the technology and receive certain milestone payments, the licenses require that up to 40 percent of the milestone amount be paid to the licensors. Additional terms of the technology licenses include annual licensing payments of $175,000 until the underlying technology has been commercialized. Terms of the licenses also include other payments to occur during commercialization that could total $950,000, payment of $350,000 upon a change in control of ownership, payments of up to $300,000 annually to extend filing periods related to certain technology, and payment of patent filing, maintenance, and defense fees. The license terms remain in effect until the last patent expires.
	In connection with our development activities, we periodically enter into contracts with consultants and vendors. These contracts are generally cancelable with 30 days’ written notice. As of December 31, 2013, the minimum future payments on these contracts totaled approximately $227,000.
	We currently lease our office and lab facilities under a non-cancelable operating lease that expires in January 2018. The lease contains fixed annual escalations, an option for a five-year extension, leasehold improvement allowances and credits of $523,000, and rent abatements of $136,000. We record rent expense on a straight-line basis over the life of the lease; the difference between average rent expense and cash payments for rent is recorded as a deferred liability. As of December 31, 2013, our deferred rent totaled $578,000, of which $98,000 was classified as a current liability. We recorded rent expense of $502,000, $636,000, $666,000, and $4.75 million for the years ended December 31, 2011, 2012, and 2013 and for the period from June 3, 1998 (inception) through December 31, 2013, respectively.
	Future minimum payments under the lease as of December 31, 2013 are as follows:
		Minimum
		Payment
		(in thousands)
	2014	$	625
	2015	645
	2016	690
	2017	711
	2018	60
	Total minimum lease payments	$	2,731

Related_Parties

Related Parties	12 Months Ended
	Dec. 31, 2013
Related Parties	'
Related Parties	'
	9.  Related Parties
	Our related parties include the members of our board of directors and investors with five percent or more of our outstanding securities. Transactions with our related parties historically consisted of notes payable issued to members of our board of directors, or firms they represented, or to the investors that held in excess of five percent of our securities. All of our notes payable together with accrued interest converted into common stock upon our initial public offering in December 2010.

Selected_Quarterly_Financial_I

Selected Quarterly Financial Information (unaudited)	12 Months Ended
	Dec. 31, 2013
Selected Quarterly Financial Information (unaudited)	'
Selected Quarterly Financial Information (unaudited)	'
	10.  Selected Quarterly Financial Information (unaudited)
	The following table presents selected quarterly financial information that has been derived from our unaudited quarterly consolidated financial statements, which, in the opinion of management, include all adjustments (consisting only of normal recurring items) necessary for a fair presentation. The quarterly per share data presented below was calculated separately and may not sum to the annual figures presented in the consolidated financial statements. These operating results are also not necessarily indicative of results for any future period.
		Quarter Ended												Year Ended
		March 31,			June 30,			September 30,			December 31,			December 31,
		(in thousands, except per share amounts)
	2012:00:00
	Loss from operations	$	(5,721	)	$	(5,950	)	$	(5,849	)	$	(6,345	)	$	(23,865	)
	Net loss	(5,698		)	(5,915		)	(5,834		)	(6,329		)	(23,776		)
	Net loss per common share, basic and diluted	$	(0.17	)	$	(0.18	)	$	(0.18	)	$	(0.19	)	$	(0.72	)
	2013:00:00
	Loss from operations	$	(6,343	)	$	(6,666	)	$	(7,182	)	$	(7,752	)	$	(27,943	)
	Net loss	(6,331		)	(6,647		)	(7,191		)	(7,753		)	(27,922		)
	Net loss per common share, basic and diluted	$	(0.19	)	$	(0.20	)	$	(0.22	)	$	(0.23	)	$	(0.84	)

Stage_of_Company_Capital_Resou1

Stage of Company, Capital Resources, and Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2013
Stage of Company, Capital Resources, and Basis of Presentation	'
Development Stage	'
	Development Stage:  We are considered a “development stage” entity, as we have not yet generated revenues from the sale of products. We have been researching and developing new technologies and product applications and have conducted human clinical trials of our bioresorbable stent. We will continue as a development stage entity, including reporting “inception to-date” amounts and cumulative equity transactions, until such time, if any, as we generate revenue.
Capital Resources and Going Concern	'
	Capital Resources and Going Concern:  We have experienced recurring losses and negative cash flows from operating activities since our inception and, as of December 31, 2013, we had a deficit accumulated during the development stage of $201,509,000. Until we generate a level of revenue to support our cost structure, we expect to continue to incur substantial operating losses and net cash outflows. While we had cash and investments totaling $20,721,000 as of December 31, 2013, we do not believe these resources will be sufficient to meet our operating and capital needs through 2014.
	We intend to fund our ongoing activities by utilizing our current cash and investments and by raising additional capital through equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. If we are unable to raise sufficient additional capital, we may be compelled to reduce the scope of our operations and planned capital expenditures or sell certain assets, including intellectual property assets.
	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Given our current cash and investment balances and our planned operating activities, our recurring losses and negative cash flows from operating activities raise substantial doubt about our ability to continue as a going concern. Even if we are able to raise additional capital, we may never become profitable, or if we do attain profitable operations, we may not be able to sustain profitability and positive cash flows on a recurring basis.
Basis of Presentation	'
	Basis of Presentation:  We have prepared the accompanying consolidated financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of REVA and our wholly owned subsidiary, REVA Germany GmbH. All intercompany transactions and balances, if any, have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates:  In order to prepare our financial statements in conformity with accounting principles generally accepted in the United States, we are required to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Our most significant estimates relate to, or have related to, expense accruals and fair market value determinations of notes payable and embedded conversion features, common and preferred stock warrants, preferred stock rights liability, and stock-based compensation. Actual results could differ from our estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents:  All highly liquid investments with original maturities of three months or less are classified as cash equivalents.
Investments	'
	Investments:  Excess cash is invested in high-quality marketable securities. Our investments are classified as either short- or long-term based on their maturity dates. Investments with a maturity of less than one year are classified as short-term; all others are classified as long-term. We have categorized the investments as “held-to-maturity” based on our intent and ability to hold to maturity. Our investments are stated at cost; their fair value is determined each reporting period through quoted market prices of similar instruments in active markets. During the reporting period there were no declines in fair value that were deemed to be other than temporary.
Property and Equipment	'
	Property and Equipment:  Property and equipment is stated at cost, less accumulated depreciation and amortization. Depreciation is determined using the straight-line method over the estimated useful lives of the related assets, generally three to five years. Amortization of leasehold improvements is determined using the straight-line method over the lesser of the useful life of the asset or the term of the underlying lease. Upon disposition or retirement of an asset, its cost and related accumulated depreciation or amortization are removed from the accounts and any gain or loss is recognized in the consolidated statement of operations.
Patents	'
	Patents:  Costs related to patent development, filing, and maintenance are expensed as incurred since the underlying technology associated with these assets is purchased or incurred in connection with our research and development efforts and the future realizable value cannot be determined.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets:  We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable and exceeds its undiscounted future cash flows. The amount of impairment, if any, is determined by comparing an asset’s estimated fair value to the asset’s respective carrying amount. During the years ended December 31, 2011, 2012, and 2013 we determined there were no indications of asset impairment. During the period from June 3, 1998 (inception) through December 31, 2013, we recorded $502,000 in losses from impairment of long-lived assets.
Concentrations of Credit Risk	'
	Concentrations of Credit Risk:  Our financial instruments, which potentially subject us to concentration of credit risk, comprise cash, cash equivalents, and investments. We maintain our cash and cash equivalents in bank accounts, the balances of which generally exceed limits that are insured by the Federal Deposit Insurance Corporation. Our investments are held in custody by a large financial asset manager in the United States. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which the assets are held. Additionally, we maintain our cash and investments in accordance with our investment policy, which is designed to maintain safety and liquidity. We have not realized any losses in our investments and believe we are not exposed to significant credit risk related to our cash and cash equivalents.
Research and Development	'
	Research and Development:  Research and development costs are expensed as incurred. These costs include salaries, employee benefits, laboratory supplies, consulting services, manufacturing products and services, preclinical and clinical costs, technology license fees, laboratory equipment depreciation, facility costs, and certain indirect costs.
Segment Information	'
	Segment Information:  We operate in one business segment, which is the development and commercialization of medical devices.
Income Taxes	'
	Income Taxes:  We account for income taxes using the asset and liability method, under which the current income tax expense or benefit is the amount of income tax expected to be payable or refundable in the current year. Deferred tax assets and liabilities are recorded for the estimated future tax consequences of temporary differences between the financial statement carrying amounts of assets and liabilities and their respective tax bases, and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled.
	We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of our deferred tax assets will not be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.
	We account for the uncertainty in income tax components based on tax positions taken or expected to be taken in a tax return. To recognize a benefit, a tax position must be more likely than not to be sustained upon examination by taxing authorities. We do not recognize tax benefits that have a less than 50 percent likelihood of being sustained. Our policy is to recognize interest and tax penalties related to unrecognized tax benefits in income tax expense; no interest or tax penalties on uncertain tax benefits have been recorded through December 31, 2013.
	We are subject to taxation in U.S. and California jurisdictions. As of December 31, 2013, our tax years beginning December 1, 1999 remain subject to examination by taxing authorities.
Stock-Based Compensation	'
	Stock-Based Compensation:  We account for stock-based compensation by measuring and recognizing expense for all stock-based payments made to employees and directors based on estimated grant date fair values. We use the straight-line method to allocate compensation expense to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimate the fair value of stock-based awards to employees and directors using the Black-Scholes option valuation model. The Black-Scholes model requires the input of assumptions, including volatility, the expected term, and the fair value of the underlying common stock on the date of grant, among other inputs. We record the option value to compensation expense based on the financial statement category for which an optionee’s services are rendered and cash compensation is recorded. We adjust stock-based compensation expense for estimated option forfeitures based on our five-year historical average of actual forfeitures.
	We account for stock options issued to consultants as expense at their fair value over the related service period, as determined in accordance with authoritative guidance. We revalue the consultants’ stock options as they vest.
Foreign Currency	'
	Foreign Currency:  The functional currency of our subsidiary REVA Germany GmbH is the Euro. Balance sheet accounts of our subsidiary are translated into United States dollars using the exchange rate in effect at the balance sheet date while expenses are translated using the average exchange rate in effect during the period. Gains and losses arising from translation of our subsidiary’s financial statements are recorded to other comprehensive income (loss). These gains and losses, in the aggregate, were insignificant through December 31, 2013.
Net Loss Per Common Share	'
	Net Loss Per Common Share:  Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method, as applicable. For purpose of this calculation, unvested restricted stock and stock options are considered to be common stock equivalents and are included in the calculation of diluted net loss per share only when their effect is dilutive.
	During the year ended December 31, 2011, we excluded options to purchase common stock of 3,324,046 shares and during the years ended December 31, 2012 and 2013, we excluded options to purchase common stock of 3,300,039 and 3,901,316 shares, respectively, and excluded 17,648 and 96,347 shares, respectively, of restricted common stock from the computation of diluted net loss per share because including them would have been antidilutive.
Fair Value Measurements	'
	Fair Value Measurements:  We measure the fair value of our financial and non-financial assets and liabilities at each reporting date. Fair value is defined as the exchange price at which an asset or liability would be transferred in the principal or most advantageous market in an orderly transaction between market participants as of a measurement date. Accounting guidance provides an established hierarchy to be used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs; observable inputs are required to be used when available. Observable inputs are those used by market participants to value an asset or liability and are developed based on market data obtained from sources independent of us. Unobservable inputs are those that reflect our assumptions about factors that market participants would use to value an asset or liability. Fair value measurements are classified and disclosed in one of the following three categories:
	Level 1 – Quoted market prices for identical assets or liabilities in active markets at the measurement date;
	Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of an asset or liability; and,
	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of an asset or liability, including management’s best estimate of the factors that market participants would use in pricing an asset or liability at the measurement date.
	We apply fair value accounting to our cash equivalents and investments. The fair values of our investments, determined from “Level 2” inputs were as follows:
		Cost		Gross			Fair
				Unrealized			Value
				Losses
		(in thousands)
	As of December 31, 2012:
	Time deposits due in one year or less	$	5,223	$	(8	)	$	5,215
	As of December 31, 2013:
	Time deposits due in one year or less	$	1,492	$	(4	)	$	1,488
Financial Statement Components Discontinued upon IPO	'
	Financial Statement Components Discontinued upon IPO:  Concurrent with the completion of our Initial Public Offering in December 2010, all of our outstanding convertible preferred stock, non-voting common stock, notes payable, and accrued interest on notes payable converted to common stock. Additionally, all outstanding warrants were exercised for common stock, either through a cash payment to us or on a net exercise basis. We also issued common stock for cumulative dividends on our Series H convertible preferred stock. Those debt and equity instruments, including accounting for warrant liabilities, note and warrant valuations, and deemed and cumulative dividends, had no effect on our financial statements after December 2010.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements:  In July 2013, the Financial Accounting Standards Board issued Accounting Standards Update No. 2013-11 (“ASU 2013-11”), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years beginning after December 15, 2013. We intend to adopt this guidance at the beginning of 2014; we do not believe the adoption of this standard will have a material impact on our financial position, results of operations or related financial statement disclosures.

Significant_Accounting_Policie1

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Significant Accounting Policies	'
Schedule of fair values of our investments, determined from "Level 2" inputs	'
		Cost		Gross			Fair
				Unrealized			Value
				Losses
		(in thousands)
	As of December 31, 2012:
	Time deposits due in one year or less	$	5,223	$	(8	)	$	5,215
	As of December 31, 2013:
	Time deposits due in one year or less	$	1,492	$	(4	)	$	1,488

Balance_Sheet_Details_Tables

Balance Sheet Details (Tables )	12 Months Ended
	Dec. 31, 2013
Balance Sheet Details	'
Schedule of components of property and equipment	'
		December 31,
		2012			2013
		(in thousands)
	Property and equipment:
	Furniture, office equipment, and software	$	569		$	656
	Laboratory equipment	3,816			4,896
	Leasehold improvements	1,838			2,305
		6,223			7,857
	Accumulated depreciation and amortization	(3,402		)	(4,268		)
		$	2,821		$	3,589
Schedule of components of accrued expenses and other current liabilities	'
	Accrued expenses and other current liabilities:
	Accrued salaries and other employee costs	$	1,123		$	1,371
	Accrued operating expenses	288			560
	Accrued use taxes and other	126			149
		$	1,537		$	2,080

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Schedule of the reconciliation between income taxes computed at the federal statutory rate and provision for income taxes	'
		Year Ended December 31,
		2011			2012			2013
		(in thousands)
	Federal income taxes at 34%	$	(7,109	)	$	(8,084	)	$	(9,493	)
	State income taxes, net of federal benefit	(1,219		)	(1,363		)	(1,553		)
	Research and development credits	(828		)	(240		)	(1,425		)
	Stock-based compensation expense	133			131			191
	Increase in valuation allowance	8,079			59,186			11,622
	Reinstatement of deferred tax assets for net operating loss and tax credit carryover deferred tax assets	—			(50,311		)	—
	Expiration of state net operating losses	—			673			677
	Other	944			8			(19		)
	Provision for income taxes	$	—		$	—		$	—
Schedule of the significant components of deferred tax assets and liabilities	'
		December 31,
		2012			2013
		(in thousands)
	Deferred Tax Assets:
	Net operating loss carryforwards	$	52,895		$	61,629
	Research and development credits	4,853			6,277
	Stock-based compensation expense	2,749			4,182
	Depreciation	177			230
	Accrued operating expenses	—			12
	Other	327			293
		61,001			72,623
	Valuation Allowance	(61,001		)	(72,623		)
	Net Deferred Income Taxes	$	—		$	—
Schedule of the reconciliation of the beginning and ending amount of gross unrecognized tax benefits for period excluding interest and penalties	'
		December 31,
		2012			2013
		(in thousands)
	Balance at Beginning of Year	$	—		$	1,954
	Additions for tax positions (prior years)	1,833			167
	Additions for tax positions (current year)	121			369
	Balance at End of Year	$	1,954		$	2,490

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Stock-Based Compensation	'
Schedule of the option activity under the plan	'
							Weighted
				Weighted			Average
				Average			Remaining		Aggregate
		Options		Exercise			Contractual		Intrinsic
		Outstanding		Price			Term (years)		Value
	Balance at December 31, 2010	3,016,800		$	5.96
	Granted	401,000		$	13.7
	Cancelled	(73,800	)	$	4.62
	Exercised	(40,000	)	$	0.79
	Balance at December 31, 2011	3,304,000		$	6.99
	Granted	544,000		$	5.95
	Cancelled	(9,300	)	$	12.64
	Exercised	(288,700	)	$	1.11
	Balance at December 31, 2012	3,550,000		$	7.3
	Granted	589,500		$	5.36
	Cancelled	(42,500	)	$	2
	Exercised	(50,350	)	$	0.61
	Balance at December 31, 2013	4,046,650		$	7.15		7.17		$	3,290,000
	Vested at December 31, 2013	2,738,501		$	7.07		5.38		$	3,267,000
	Vested and Expected to Vest at December 31, 2013	4,014,994		$	7.03		6.34		$	3,289,000
Schedule of the vesting activity under the plan	'
				Weighted
				Average
		Options		Grant Date
		Outstanding		Fair Value
	Unvested Options at December 31, 2012	1,471,925		$	5.16
	Granted	589,500		$	2.95
	Vested	(747,443	)	$	5.13
	Forfeited	(5,833	)	$	3.77
	Unvested Options at December 31, 2013	1,308,149		$	4.2
Options Granted	'
Stock-Based Compensation	'
Schedule of the expense (income) recorded under the plan	'
		Year Ended December 31,
		2011			2012			2013
		(in thousands)
	Research and development	$	688		$	832		$	1,069
	General and administrative	2,452			2,647			2,965
	Total stock-based compensation	$	3,140		$	3,479		$	4,034
Schedule of the weighted-average assumptions used to estimate fair value of options granted	'
		Year Ended December 31,
		2011		2012		2013
	Risk-free interest rate	2.68	%	1.03	%	1.38	%
	Expected volatility of common stock	63.9	%	62.1	%	60.1	%
	Expected life in years	6.25		6.25		6.25
	Dividend yield	0	%	0	%	0	%
Schedule of the grant date fair value and intrinsic value information of options granted to employees	'
		Year Ended December 31,
		2011			2012			2013
		(in thousands, except per share data)
	Weighted average grant date fair value per share	$	8.35		$	3.43		$	2.95
	Intrinsic value of options exercised	$	249		$	1,392		$	231
	Total fair value of options vested during period	$	3,140		$	3,802		$	3,809
Stock Options to Consultants	'
Stock-Based Compensation	'
Schedule of the weighted-average assumptions used to estimate fair value of options granted	'
		Year Ended December 31,
		2011		2012		2013
	Risk-free interest rate	1.62	%	1.18	%	2.96	%
	Expected volatility of common stock	62.1	%	62.1	%	59.4	%
	Expected life – years	7.71		6.71		9.45
	Dividend yield	0	%	0	%	0	%
Stock options to consultants and stock awards	'
Stock-Based Compensation	'
Schedule of the expense (income) recorded under the plan	'
		Year Ended December 31,
		2011			2012			2013
		(in thousands)
	Research and development	$	(51	)	$	18		$	9
	General and administrative	—			—			47
	Total stock-based compensation	$	(51	)	$	18		$	56

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies.	'
Schedule of the future minimum payments under the lease	'
	Future minimum payments under the lease as of December 31, 2013 are as follows:
		Minimum
		Payment
		(in thousands)
	2014	$	625
	2015	645
	2016	690
	2017	711
	2018	60
	Total minimum lease payments	$	2,731

Selected_Quarterly_Financial_I1

Selected Quarterly Financial Information (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Selected Quarterly Financial Information (unaudited)	'
Schedule of the selected quarterly financial information	'
		Quarter Ended												Year Ended
		March 31,			June 30,			September 30,			December 31,			December 31,
		(in thousands, except per share amounts)
	2012:00:00
	Loss from operations	$	(5,721	)	$	(5,950	)	$	(5,849	)	$	(6,345	)	$	(23,865	)
	Net loss	(5,698		)	(5,915		)	(5,834		)	(6,329		)	(23,776		)
	Net loss per common share, basic and diluted	$	(0.17	)	$	(0.18	)	$	(0.18	)	$	(0.19	)	$	(0.72	)
	2013:00:00
	Loss from operations	$	(6,343	)	$	(6,666	)	$	(7,182	)	$	(7,752	)	$	(27,943	)
	Net loss	(6,331		)	(6,647		)	(7,191		)	(7,753		)	(27,922		)
	Net loss per common share, basic and diluted	$	(0.19	)	$	(0.20	)	$	(0.22	)	$	(0.23	)	$	(0.84	)

Description_of_Business_Detail

Description of Business (Details) (USD $)	12 Months Ended		1 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2010	Dec. 31, 2010
	item	CDI	Common stock
Description of Business	'	'	'
Number of patients enrolled in a clinical trial of current stent product	111	'	'
Description of Business	'	'	'
Common Stock issued	'	'	7,727,273
Proceeds from issuance of common stock	'	'	$75,790
Common stock to CDIs conversion ratio	'	10	'

Stage_of_Company_Capital_Resou2

Stage of Company, Capital Resources, and Basis of Presentation (Details) (USD $)	Dec. 31, 2013
Initial Public Offering	'
Deficit accumulated during the development stage	$201,509,000
Cash and investments	$20,721,000

Significant_Accounting_Policie2

Significant Accounting Policies (Details) (USD $)	12 Months Ended	187 Months Ended
	Dec. 31, 2013	Dec. 31, 2013
	segment
Property and Equipment:	'	'
Impairment of long lived assets	'	$502,000
Number of business segment	1	'
Interest or tax penalties on uncertain tax benefits	$0	'
Historical average period of actual forfeitures	'5 years	'
Minimum	'	'
Property and Equipment:	'	'
Property and equipment, useful life	'3 years	'
Maximum	'	'
Property and Equipment:	'	'
Property and equipment, useful life	'5 years	'

Significant_Accounting_Policie3

Significant Accounting Policies (Details 2)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Common stock options	'	'	'
Net Income Loss Per Common Share	'	'	'
Securities excluded from the computation of diluted net loss per share (in shares)	3,901,316	3,300,039	3,324,046
Restricted Stock	'	'	'
Net Income Loss Per Common Share	'	'	'
Securities excluded from the computation of diluted net loss per share (in shares)	96,347	17,648	'

Significant_Accounting_Policie4

Significant Accounting Policies (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Significant Accounting Policies	'	'
Cost, one year or less	$1,492	$5,223
Gross Unrealized loss	-4	-8
Fair Value	$1,488	$5,215

Balance_Sheet_Details_Details

Balance Sheet Details (Details ) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property and equipment:	'	'
Property and equipment, gross	$7,857	$6,223
Accumulated depreciation and amortization	-4,268	-3,402
Property and equipment, net	3,589	2,821
Furniture, office equipment, and software	'	'
Property and equipment:	'	'
Property and equipment, gross	656	569
Laboratory equipment	'	'
Property and equipment:	'	'
Property and equipment, gross	4,896	3,816
Leasehold improvements	'	'
Property and equipment:	'	'
Property and equipment, gross	$2,305	$1,838

Balance_Sheet_Details_Details_

Balance Sheet Details (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued expenses and other current liabilities:	'	'
Accrued salaries and other employee costs	$1,371	$1,123
Accrued operating expenses	560	288
Accrued use taxes and other	149	126
Accrued expenses and other current liabilities, total	$2,080	$1,537

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation between income taxes computed at the federal statutory rate and provision for income taxes	'	'	'
Federal income taxes at 34%	($9,493)	($8,084)	($7,109)
State income taxes, net of federal benefit	-1,553	-1,363	-1,219
Research and development credits	-1,425	-240	-828
Stock-based compensation expense	191	131	133
Increase in valuation allowance	11,622	59,186	8,079
Reinstatement of deferred tax assets for net operating loss and tax credit carryover deferred tax assets	'	-50,311	'
Expiration of state net operating losses	677	673	'
Other	($19)	$8	$944
Federal income tax rate	34.00%	34.00%	34.00%

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Tax Assets:	'	'
Net operating loss carryforwards	$61,629	$52,895
Research and development credits	6,277	4,853
Stock-based compensation expense	4,182	2,749
Depreciation	230	177
Accrued operating expenses	12	'
Other	293	327
Deferred Tax Assets	72,623	61,001
Valuation Allowance	($72,623)	($61,001)

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Taxes	'	'
Net operating loss related to excess tax benefits from stock compensation	$267,000	'
Deferred tax assets	72,623,000	'
Change in valuation allowance	11,622,000	59,187,000
Unrecognized tax benefits	2,490,000	1,954,000
Federal	'	'
Income Taxes	'	'
Net operating loss carryforwards	158,916,000	'
Research tax credit carryforward, amount	5,278,000	'
California State	'	'
Income Taxes	'	'
Net operating loss carryforwards	132,037,000	'
Net operating loss carryforwards with expiration in 2014	7,712,000	'
Research tax credit carryforward, amount	$4,684,000	'

Income_Taxes_Details_4

Income Taxes (Details 4) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Income Tax Contingency	'	'
Balance at Beginning of Year	$1,954	'
Additions for tax positions (prior years)	167	1,833
Additions for tax positions (current year)	369	121
Balance at End of Year	$2,490	$1,954

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Options Outstanding	'	'	'
Granted (in shares)	589,500	'	'
Options	'	'	'
Stock-Based Compensation	'	'	'
Term of options granted under the plan	'10 years	'	'
Plan	'	'	'
Stock-Based Compensation	'	'	'
Number of plans covered under stock-based compensation arrangement	2	'	'
Number of shares added in reserve	993,966	'	'
Total number of shares in reserve with additional shares under the Plan	6,545,884	'	'
Aggregate Intrinsic Value	'	'	'
Tax benefits from stock based compensation	$0	'	'
Plan | Minimum	'	'	'
Stock-Based Compensation	'	'	'
Vesting periods	'4 years	'	'
Plan | Maximum	'	'	'
Stock-Based Compensation	'	'	'
Increment in the number of shares reserved under the Plan annually (as a percent)	3.00%	'	'
Term of options granted under the plan	'10 years	'	'
Vesting periods	'5 years	'	'
Plan | Options	'	'	'
Options Outstanding	'	'	'
Balance at the beginning of period (in shares)	3,550,000	3,304,000	3,016,800
Granted (in shares)	589,500	544,000	401,000
Cancelled (in shares)	-42,500	-9,300	-73,800
Exercised (in shares)	-50,350	-288,700	-40,000
Balance at the end of period (in shares)	4,046,650	3,550,000	3,304,000
Vested at end of year (in shares)	2,738,501	'	'
Vested and Expected to vest at the end of period (in shares)	4,014,994	'	'
Weighted Average Exercise Price	'	'	'
Balance at the beginning of period (in dollars per share)	$7.30	$6.99	$5.96
Granted (in dollars per share)	$5.36	$5.95	$13.70
Cancelled (in dollars per share)	$2	$12.64	$4.62
Exercised (in dollars per share)	$0.61	$1.11	$0.79
Balance at the end of period (in dollars per share)	$7.15	$7.30	$6.99
Vested at end of year (in dollars per share)	$7.07	'	'
Vested and Expected to vest at the end of period (in dollars per share)	$7.03	'	'
Weighted Average Remaining Contractual Term	'	'	'
Balance at end of year	'7 years 2 months 1 day	'	'
Vested at end of year	'5 years 4 months 17 days	'	'
Vested and Expected to vest at the end of period	'6 years 4 months 2 days	'	'
Aggregate Intrinsic Value	'	'	'
Balance at end of year (in dollars)	3,290,000	'	'
Vested at end of year (in dollars)	3,267,000	'	'
Vested and Expected to vest at the end of period (in dollars)	$3,289,000	'	'
Plan | Restricted Stock	'	'	'
Aggregate Intrinsic Value	'	'	'
Number of shares awarded	87,500	33,000	'
Annual vesting percent	25.00%	'	'

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013
Options Outstanding	'
Balance at the beginning of the period (in shares)	1,471,925
Granted (in shares)	589,500
Vested (in shares)	-747,443
Forfeited (in shares)	-5,833
Balance at the end of the period (in shares)	1,308,149
Weighted Average Grant Date Fair Value	'
Balance at the beginning of the period (in dollars per share)	$5.16
Weighted average grant date fair value (in dollars per share)	$2.95
Vested (in dollars per share)	$5.13
Forfeited (in dollars per share)	$3.77
Balance at the end of the period (in dollars per share)	$4.20

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 3) (Stock Awards and Option Grants, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock Options and Restricted Stock to Employees	'	'	'
Total stock-based compensation	$4,034,000	$3,479,000	$3,140,000
Unrecognized compensation cost	4,587,000	'	'
Unrecognized compensation cost related to unvested employee options, period for recognition	'1 year 6 months 4 days	'	'
Research and development	'	'	'
Stock Options and Restricted Stock to Employees	'	'	'
Total stock-based compensation	1,069,000	832,000	688,000
General and administrative	'	'	'
Stock Options and Restricted Stock to Employees	'	'	'
Total stock-based compensation	$2,965,000	$2,647,000	$2,452,000

StockBased_Compensation_Detail3

Stock-Based Compensation (Details 4) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2010

Options Granted

Options Granted

Options Granted

Stock Options to Consultants

Stock Options to Consultants

Stock Options to Consultants

Stock Options to Consultants

Stock Options to Consultants

Stock Options to Consultants

Stock options to consultants and stock awards

Stock options to consultants and stock awards

Stock options to consultants and stock awards

Stock options to consultants and stock awards

Stock options to consultants and stock awards

Stock options to consultants and stock awards

Stock options to consultants and stock awards

Non-Plan Options

Non-Plan Options

Minimum

Maximum

Research and development

Research and development

Research and development

General and administrative

Additional information related to fair values of options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate (as a percent)

'

1.38%

1.03%

2.68%

'

2.96%

1.18%

1.62%

'

'

'

'

'

'

'

'

'

'

'

Expected volatility of common stock (as a percent)

'

60.10%

62.10%

63.90%

'

59.40%

62.10%

62.10%

'

'

'

'

'

'

'

'

'

'

'

Expected life

'

'6 years 3 months

'6 years 3 months

'6 years 3 months

'

'9 years 5 months 12 days

'6 years 8 months 16 days

'7 years 8 months 16 days

'5 years 8 months 12 days

'9 years 9 months 18 days

'

'

'

'

'

'

'

'

'

Dividend yield (as a percent)

'

0.00%

0.00%

0.00%

'

0.00%

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

Expiration term

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum risk-free interest rate (as a percent)

'

'

'

'

'

1.20%

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum risk-free interest rate (as a percent)

'

'

'

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum assumed expected volatility (as a percent)

'

'

'

'

'

59.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum assumed expected volatility (as a percent)

'

'

'

'

'

62.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average grant date fair value (in dollars per share)

$2.95

$2.95

$3.43

$8.35

'

$2.84

$4.37

$5.24

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of options exercised

'

$231,000

$1,392,000

$249,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total fair value of options vested during period

'

3,809,000

3,802,000

3,140,000

'

40,000

42,000

57,000

'

'

'

'

'

'

'

'

'

'

'

Shares issued

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

589,500

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total stock-based compensation

'

'

'

'

'

'

'

'

'

'

$56,000

$18,000

($51,000)

$9,000

$18,000

($51,000)

$47,000

'

'

Exercised (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

Expired options (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

Outstanding options (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

10,000

Retirement_Plan_Details

Retirement Plan (Details) (USD $)	12 Months Ended			187 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Retirement Plan	'	'	'	'
Matching contributions equal to the percentage of the employee's contribution	25.00%	'	'	'
Employer matching contribution, (as a percent)	4.00%	'	'	'
Contributions by employer	$52,000	$46,000	$40,000	$309,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	12 Months Ended			187 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Commitment and Contingencies	'	'	'	'
License provisions for escalating minimum royalties	$2,200,000	'	'	'
Annual licensing payment	175,000	'	'	'
Other payments of royalty agreement occur during commercialization	950,000	'	'	'
Payment due to change in control of ownership	350,000	'	'	'
Contract cancelable period with written notice	'30 days	'	'	'
Minimum future payments on contracts	227,000	'	'	227,000
Operating Lease Extended Term	'5 years	'	'	'
Leasehold improvements allowance and credit	523,000	'	'	'
Rent abatement	136,000	'	'	'
Deferred rent recorded in long-term liability	578,000	'	'	578,000
Deferred rent recorded in Current liability	98,000	'	'	98,000
Rent expense	666,000	636,000	502,000	4,750,000
Minimum	'	'	'	'
Commitment and Contingencies	'	'	'	'
Royalty payment per unit (in dollar per unit)	25	'	'	'
Maximum	'	'	'	'
Commitment and Contingencies	'	'	'	'
Royalty payment per unit (in dollar per unit)	100	'	'	'
Milestone amounts paid to the licensors (as a percent)	40.00%	'	'	'
Annual payments to extend filing periods related to certain technology	$300,000	'	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies (Details 2) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Future minimum payments	'
2014	$625
2015	645
2016	690
2017	711
2018	60
Total minimum lease payments	$2,731

Related_Parties_Details

Related Parties (Details) (Minimum)	Dec. 31, 2013
Minimum	'
Related Party Transaction	'
Ownership percentage of outstanding securities required to be considered as related party	5.00%

Selected_Quarterly_Financial_I2

Selected Quarterly Financial Information (unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended			187 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Selected Quarterly Financial Information (unaudited)	'	'	'	'	'	'	'	'	'	'	'	'
Loss from operations	($7,752)	($7,182)	($6,666)	($6,343)	($6,345)	($5,849)	($5,950)	($5,721)	($27,943)	($23,865)	($21,096)	($167,417)
Net Loss	($7,753)	($7,191)	($6,647)	($6,331)	($6,329)	($5,834)	($5,915)	($5,698)	($27,922)	($23,776)	($20,908)	($197,336)
Net loss per common share, basic and diluted (in dollars per share)	($0.23)	($0.22)	($0.20)	($0.19)	($0.19)	($0.18)	($0.18)	($0.17)	($0.84)	($0.72)	($0.64)	'